Gene & Cell Therapy and Rare Diseases’ Research
We conduct extensive research into the rapidly evolving gene and cell therapy and rare diseases arena to empower clients to win. Our strategic insights identify key players and developments, tailored to support BioPharma partners across R&D, clinical, regulatory, and commercial endeavors.
The gene and cell therapy space has advanced rapidly, with new assets targeting therapeutic areas such as oncology, immunology, cardiovascular, CNS, and rare diseases. With multiple companies active and new approvals happening, it’s critical to get strategic insights, whether you are a BioPharma company or investor.
Our services include (amongst others):
For BioPharma clients:
- Market and competitor insights on R&D, clinical development and commercial activities
- Extensive congress coverage, supporting brand owners with up-to-date intelligence
- Landscape analysis strengthened by expert interviews
- BD&L support
For Investors:
- Due diligence research
- New opportunity identification
- Access to experts’ opinion through a combination of in-house expertise and conduct of bespoke interviews
We also invite you to join our LinkedIn Gene, Cell and RNA Therapy Strategy Network group – a hub for networking and information.
Want to better understand and succeed in this complex space? Let’s connect!
Reach out to info@lqventures.com to learn more about our strategic consulting and research capabilities.
June 4, 2026
Ascidian and Lilly $1.9B Deal for Kidney RNA Editing | Lucid Diligence Brief
June 4, 2026
IDEAYA and Roche Collaboration | Lucid Diligence Brief
June 4, 2026
Cell and Gene Therapy Today—June 4, 2026
June 4, 2026
Cardiovascular Today—June 4, 2026
June 4, 2026
Rare Diseases Today—June 4, 2026
June 4, 2026
Why Lower Reactogenicity Alone Will Not Disrupt the Next-Generation Shingles Vaccine Market
June 3, 2026
Immunology Today—June 3, 2026
June 3, 2026
Neuroscience Today—June 3, 2026
June 2, 2026
Rallybio Avenzo Merger and $215M Financing | Lucid Diligence Brief
June 2, 2026
Obesity Today—June 2, 2026
June 2, 2026
Servier Edgewise Sevasemten Deal | Lucid Diligence Brief
June 2, 2026